Immunexpress Aims To Leverage Anti-Infection Incentives For Sepsis Diagnostic
This article was originally published in Start Up
Immunexpress' SeptiCyte system is designed to directly quantify molecular markers of sepsis from patient blood samples and within a few hours detect the probability that a patient has sepsis, allowing for aggressive treatment, or if the test result is negative, preventing unnecessary antibiotics.
You may also be interested in...
The market for diagnostic and infection control products will see continued growth as hospitals and other providers look to the technology sector to help fight the battle against health care-associated infections and antibiotic-resistant organisms.
Start-ups developing technologies to help hospitals avoid preventable medical errors known as “never events” are developing solutions to nosocomial infections, retained surgical objects, pressure ulcers, and medication errors.
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.